Loading page
Loading page
Loading substance route
Requires sublingual administration with 15-25 minute absorption period; oral administration is ineffective. Produces strong metallic taste and oral numbness persisting up to one hour. Heavy doses carry extreme overdose risk and have been implicated in fatalities. Insufflation strongly discouraged due to rapid absorption, measurement difficulty, and fatal overdose potential.
Effects vary widely by individual, dose, and context.
The physical effects of 25D-NBOMe can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of 25D-NBOMe are remarkably light and underwhelming in comparison to more traditional psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout moderate to high doses. At heavy doses, however, mild cognitive alterations become present; this dose seems to be lower in proportion to physical effects when compared to 25I-NBOMe.
25D-NBOMe presents a mild array of possible visual enhancements.
The visual geometry that is present throughout this trip is often described as very similar in appearance to that of DOM. It can be comprehensively described as smooth and organic in style, simple in complexity, fine and zoomed out in detail, slow and fluid in motion, structured in shape, colourful in scheme, bright in colour, and rounded across its corners. In terms of its behaviour, 25D-NBOMe's geometry leads onto level 8A visual geometry with level 8B remaining so far unconfirmed within this substance. It also seems to consistently build up in visual intensity when the tripper stares at a central point. This eventually envelopes the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of physical size attributed to it.
25D-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently within doses higher than of 2mg.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
While formal studies are lacking, 25D-NBOMe appears to have self-regulating qualities due to rapid tolerance buildup lasting 2-3 weeks, which makes compulsive use difficult. However, animal studies have demonstrated reinforcing effects including conditioned place preference, self-administration, and increased dopaminergic signaling in the nucleus accumbens.
The LD50 has not been determined. Anecdotal reports suggest dangerous side effects may appear when exceeding 1000 µg, with potentially lethal outcomes in sensitive individuals at approximately 2000 µg. However, considerable individual variability exists, with some individuals surviving much higher doses without major effects. The NBOMe series has been linked to numerous overdoses and fatalities, particularly when insufflated or vaporized. Closely related analogs like 25I-NBOMe have been associated with many deaths and hospitalizations.
Acute cardiovascular stress including elevated blood pressure, tachycardia, abnormal heartbeat, and significant vasoconstriction occurs during intoxication; at overdose levels, these effects can become dangerous and may progress to cardiac arrest.
Anxiety and paranoia occur more readily than with many classical psychedelics, possibly due to prominent stimulating properties. Overdose can produce confusion, delusions, panic attacks, and aggressive behavior. Feelings of impending doom may occur during comedowns or at high doses.
NBOMes are known to cause seizures and have shown a tendency to cause severe seizures. Overdose is often accompanied by seizures. The unpredictable dose-response relationship increases seizure risk at doses that might otherwise be considered within normal range.
25D-NBOMe is a derivative of the phenethylamine psychedelic 2C-D, created through the addition of an N-benzyl methoxy group to the parent compound. The substance emerged on the designer drug market around 2010, appearing for sale online before formal scientific characterization had been completed.…
Controlled under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are prohibited.
Considered a Schedule III substance under the Controlled Drugs and Substances Act as a derivative of 2,5-dimethoxyphenethylamine.
Listed in the government decree on prohibited psychoactive substances in consumer markets.
Designated as a controlled substance effective March 25, 2015.
Added to Schedule I (substances without recognized medical use) as of August 1, 2013, as published by the Medical Products Agency in regulation LVFS 2013:15.
Classified as a controlled drug. Possession, production, supply, and importation are prohibited.
Not specifically scheduled at the federal or state level. However, prosecution under the Federal Analogue Act may be possible when sold for human consumption due to structural and functional similarity to the controlled substance 2C-D.
Listed as a controlled substance under Portaria SVS/MS nº 344. Possession, production, and sale are prohibited.
Designated as a controlled substance as of October 2015.
Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production, import for distribution, administration to others, and trading are criminal offenses. Possession is prohibited but not subject to criminal penalty.
Classified as a Schedule I controlled substance under national drug legislation.
Specifically named as a controlled substance under Verzeichnis E of the Swiss narcotics scheduling system.
Controlled as a Class A substance under the Misuse of Drugs Act 1971 via the N-benzylphenethylamine catch-all clause. Initially placed under a Temporary Class Drug Order on June 10, 2013 before permanent scheduling.
14 sources cited
